







The Roles of ROS Generation in RANKL-Induced 
Osteoclastogenesis: Suppressive Effects of Febuxostat 




Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, 
Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda, Kotaro 
Tanimoto, So Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro 
Oura, Kimiko Sogabe, Shingen Nakamura, Shiro Fujii, Ryohei 
Sumitani, Hirokazu Miki, Kengo Udaka, Mamiko Takahashi, 
Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and 
Masahiro Abe 
Background: Multiple myeloma (MM) has a unique propensity to almost 
exclusively develop in the bone marrow and generates devastating bone 
destruction. MM cells enhance osteoclast (OC) formation and activity and 
suppress osteoblastic differentiation from bone marrow stromal cells, 
leading to extensive bone destruction with rapid loss of bone. Receptor 
activator of NF-κB ligand (RANKL), a critical mediator of 
osteoclastogenesis, is upregulated in bone marrow stromal cells to 
extensively enhance osteoclastogenesis and bone resorption in MM; 
importantly, activated OCs in turn enhance glycolysis in MM cells and 
thereby MM cell proliferation, leading to the formation of a progressive 
vicious cycle between MM tumor expansion and osteoclastic bone 
destruction. Therefore, OCs should be targeted to improve treatment 
efficacy. Furthermore, Reactive oxygen species (ROS) is induced and plays 
important roles in a variety of pathological cellular processes. It’s produced 
during RANKL-induced osteoclastogenesis from bone marrow 
monocyte–macrophage lineage cells (BMMs), and antioxidants, including 
N-acetylcysteine (NAC), have been proven to prevent the RANKL-induced 
OC differentiation by decreasing ROS. Anticancer agents like doxorubicin 
(Dox) induce excessive levels of ROS leading to cell death. 
 
 
Purpose: We’d like to clarify the role of cancer-treatment-induced ROS in 
RANKL-mediated osteoclastogenesis and the suppressive effects of 
febuxostat on ROS generation and osteoclastogenesis. 
 
Materials and methods:  We used ovariectomized female mice to induce 
osteoporosis and compare the μ-CT results of oral administration of 
febuxostat with the control group. Furthermore, the analysis of osteoclast 
formation from murine preosteoclastic cell line RAW264.7 cells or mouse 
bone marrow cells, TRAP staining, bone resorption assay, quantification of 
ROS through the use of CellRox Green staining uder the microplate reader 
Spectramax i3, Reverse Transcription Polymeraze Chain Reaction (RT-PCR) 
and Real time-PCR, Western blot, actin ring staining and immunofluresence 
staining were conducted. 
 
Results: Dox Facilitates RANKL-Mediated Osteoclastogenesis Through ROS 
Production and febuxostat effectively suppressed the ROS production and 
thereby osteoclastogenesis by Dox and RANKL in combination. 
Furthermore, febuxostat was able to inhibit osteoclastogenesis enhanced in 
cocultures of bone marrow cells with MM cells and alleviated pathological 
bone loss in ovariectomized mice. In addition, febuxostat rather suppressed 
MM cell viability without compromising Dox’s anti-MM activity. Therefore, 
a therapeutic impact of febuxostat can be expected against cancer-induced 
pathological bone damage and CTIBL. 
 
Discussion: Cancer patients have a greater chance of living longer owing to 
recent improvement of anticancer treatment modalities. However, bone loss 
emerges as one of the most serious unmet issues associated with long-term 
repeated treatment with anticancer agents, which can be called Cancer 
Treatment Induced Bone Loss (CTIB) . The present study suggests that 
excessive ROS production by aberrant RANKL overexpression in MM and/or 
anticancer treatment disadvantageously impacts bones, leading to 
pathological bone damage and CTIBL. ROS scavenging agents such as 
febuxostat may help to prevent CTIBL. The preventive activity of febuxostat 
against CTIBL should be validated in well-designed clinical studies. 
As a dentist I believe that these findings can be of use in providing a better 
quality of life for patients affected by cancer as well as in the exploration of 
 
the possibility of using them in other areas of bone loss such as those in 
periodontitis and peri-implantitis. 
 
